In Brief: Invacare/Healthdyne
This article was originally published in The Gray Sheet
Invacare/Healthdyne: Invacare increases to $15-per-share its hostile bid to acquire respiratory product firm Healthdyne Technologies. Invacare's March 31 offer of $13.50-per-share was rejected by Healthdyne's board on April 3 as inadequate ("The Gray Sheet" April 7, I&W-2). The sweetened offer represents Invacare's "best and final offer," the firm states. Invacare initiated the acquisition effort on Jan. 2 with an initial offer of $12.50 per share...
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.